XTL Biopharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2024: 9.03%

XTL Biopharmaceuticals Ltd (H2K2) has an Asset Resilience Ratio of 9.03% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check XTL Biopharmaceuticals Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€772.00K

≈ $902.55K USD Cash + Short-term Investments

Total Assets

€8.55 Million

≈ $10.00 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how XTL Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See XTL Biopharmaceuticals Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down XTL Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is XTL Biopharmaceuticals Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€772.00K	9.03%
Total Liquid Assets	€772.00K	9.03%

Asset Resilience Insights

Limited Liquidity: XTL Biopharmaceuticals Ltd maintains only 9.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

XTL Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare XTL Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for XTL Biopharmaceuticals Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for XTL Biopharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.03%	€772.00K ≈ $902.55K	€8.55 Million ≈ $10.00 Million	-15.91pp
2023-12-31	24.94%	€605.00K ≈ $707.31K	€2.43 Million ≈ $2.84 Million	-13.93pp
2022-12-31	38.87%	€1.63 Million ≈ $1.90 Million	€4.19 Million ≈ $4.89 Million	-8.85pp
2021-12-31	47.72%	€3.16 Million ≈ $3.69 Million	€6.62 Million ≈ $7.74 Million	+10.64pp
2020-12-31	37.08%	€2.41 Million ≈ $2.82 Million	€6.50 Million ≈ $7.60 Million	+5.56pp
2019-12-31	31.52%	€2.27 Million ≈ $2.66 Million	€7.21 Million ≈ $8.43 Million	-25.24pp
2018-12-31	56.76%	€4.87 Million ≈ $5.69 Million	€8.57 Million ≈ $10.03 Million	+14.17pp
2017-12-31	42.59%	€2.81 Million ≈ $3.28 Million	€6.59 Million ≈ $7.70 Million	+28.87pp
2016-12-31	13.72%	€414.00K ≈ $484.01K	€3.02 Million ≈ $3.53 Million	--

pp = percentage points

About XTL Biopharmaceuticals Ltd

F:H2K2 Germany Biotechnology

Market Cap

$6.31 Million

€5.39 Million EUR

Market Cap Rank

#30399 Global

#2676 in Germany

Share Price

€2.28

Change (1 day)

+23.24%

52-Week Range

€0.45 - €2.80

All Time High

€8.26